Peptide Schedule
Calcitonin (Miacalcin)32 residuesCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Calcitonin (Miacalcin) Dosage Calculator
Calcitonin is a 32-amino-acid peptide hormone naturally produced by the parafollicular C-cells of the thyroid gland.
50mcg · Daily
Summary: Add 0mL BAC water to your 0.5mg vial. Draw to < 0.1 units on a U-100 syringe for a 50mcg dose. This vial will last 0 doses.
Cycle Planner
Calcitonin (Miacalcin) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~1 hour (58-64 minutes)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Calcitonin (Miacalcin) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50 IU | Daily |
| Moderate | 100 IU | Daily |
| Aggressive | 200 IU | Daily |
Note: Calcitonin-salmon is available as a subcutaneous/intramuscular injection (Miacalcin) and a nasal spray (Fortical/Miacalcin Nasal). The injectable form delivers 200 IU/mL in pre-filled vials; typical therapeutic dose is 100 IU daily for both Paget disease and osteoporosis. For hypercalcemia, initial dosing is 4 IU/kg every 12 hours. Injection-site rotation is important to minimize local reactions. Flushing of face and hands may occur minutes after injection and usually resolves within an hour. Adequate calcium and vitamin D supplementation is essential during therapy. Serum calcium should be monitored periodically, especially early in treatment. A skin test is recommended before the first dose due to potential for allergic reactions. Tolerance can develop over months; if biochemical or clinical relapse occurs, dosage increases or temporary discontinuation may be considered. Store unopened vials refrigerated at 2-8 degrees C.
About Calcitonin (Miacalcin)
Calcitonin is a 32-amino-acid peptide hormone naturally produced by the parafollicular C-cells of the thyroid gland. The synthetic salmon form (calcitonin-salmon) used in Miacalcin and Fortical is approximately 40-50 times more potent than human calcitonin on a weight basis and has a longer duration of action, making it the preferred therapeutic variant. First approved by the FDA in 1975, calcitonin-salmon is indicated for the treatment of postmenopausal osteoporosis in women more than 5 years post-menopause, symptomatic Paget disease of bone, and hypercalcemic emergencies. The peptide works by directly binding to calcitonin receptors on osteoclasts, the cells responsible for breaking down bone tissue. This binding inhibits osteoclast-mediated bone resorption, slowing the rate at which calcium is released from bone into the bloodstream. In Paget disease, where bone turnover is pathologically accelerated, calcitonin reduces the elevated levels of serum alkaline phosphatase and urinary hydroxyproline, clinical markers of excessive bone remodeling. For osteoporosis, calcitonin helps preserve bone mineral density and has been shown to reduce the risk of new vertebral fractures. Beyond its skeletal effects, calcitonin also possesses notable analgesic properties for bone pain, which is particularly beneficial in acute vertebral fractures and Paget disease. The exact mechanism of this analgesic effect is not fully understood but may involve central endorphin-mediated pathways and direct modulation of pain-related neuropeptides. While bisphosphonates have largely supplanted calcitonin as first-line therapy for most bone disorders, calcitonin remains a valuable option for patients who cannot tolerate bisphosphonates, require rapid reduction of serum calcium, or need acute bone pain relief.